Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Farallon Capital Management

Investor type Private Equity Firm
Founders Tom Steyer


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 61
Average round size
The average size of a deal this fund participated in
Portfolio companies 51
Rounds per year 1.69
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 21
Key employees 10
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Health Diagnostics
  • Pharmaceutical

Farallon Capital Management appeared to be the VC, which was created in 1986. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the San Francisco.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Farallon Capital Management, startups are often financed by Venrock, New Leaf Venture Partners, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, Chengwei Capital, Hillhouse Capital Group. In the next rounds fund is usually obtained by Sutter Hill Ventures, Chengwei Capital, Tencent Holdings.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the various public portfolio startups of the fund, we may underline Go-Jek, Manbang Group, Intarcia Therapeutics We can highlight the next thriving fund investment areas, such as Health Care, Media and Entertainment.

This organization was formed by Tom Steyer. We also calculated 10 valuable employees in our database.

The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2006. Despite it in 2019 the fund had an activity. The average startup value when the investment from Farallon Capital Management is more than 1 billion dollars. The increased amount of exits for fund were in 2018. The usual things for fund are deals in the range of more than 100 millions dollars. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. Comparing to the other companies, this Farallon Capital Management performs on 1 percentage points less the average number of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Farallon Capital Management:
Typical Co-investors
Farallon Capital Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Farallon Capital Management:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Ambrosia Software New York, Rochester, United States
Coverys Boston, Massachusetts, United States
KCK New York, New York, United States
MDSI Mobile Data Solutions Inc. British Columbia, Canada, Richmond
Merchants Capital Partners LP New York, New York, United States
MITS Fund California, Los Altos, United States
Osaka Gas USA Houston, Texas, United States
ProSeed Venture Capital Fund Israel, Tel Aviv, Tel Aviv District
Senscape Technologies -
Two Roads Group Chicago, Illinois, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Renewable Energy
$128M21 Feb 2022 Paris, Ile-de-France, France

Beta Bionics

Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Ada Health

Artificial Intelligence
Health Care
$30M10 Feb 2022 Berlin, Berlin, Germany

Better Therapeutics

Artificial Intelligence
Health Care
Information Technology
$70M29 Oct 2021 San Francisco, California, United States

DNA Script

Health Care
Life Science
$165M26 Oct 2021 France, Ile-de-France, France


Health Care
Medical Device
$102M08 Sep 2021 Irvine, California, United States


Health Care
Health Diagnostics
Life Science
Medical Device
$375M01 Sep 2021 Boulder, Colorado, United States


Financial Services
Mobile Payments
$292M23 Aug 2021 London, England, United Kingdom

Zentera Therapeutics

$75M04 Aug 2021 Shanghai, Shanghai, China
Zepz, Formerly WorldRemit Group, the Leading Digital Cross-border Payments Platform, Has Raised $292 Million in New Primary Series E Financing, Achieving a Valuation of $5 Billion

– Zepz, formerly WorldRemit, a digital cross-border payments platform operating two market-leading brands (WorldRemit and Sendwave, acquired in 2021), with over 11 million users1 across 150 countries, announces it has raised $292m in new financing, achieving a valuation of $5bn.
– The round includes new equity investors Farallon Capital among others, as well as backing from existing investors Leapfrog, TCV and Accel.
– Zepz is revolutionizing the P2P cross-border payments market, an estimated $1tn market opportunity which continues to be predominantly offline and is characterised by high prices and poor customer experience.

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Farallon Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: